Global Vasculitis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4564304
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Baxter International
  • Celgene Corporaion
  • ChemoCentryx
  • Daiichi Sankyo
  • Eli Lilly & Company
  • MORE
Vasculitis Treatment Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026, the global vasculitis treatment market was valued at US$ 365.1 Mn in 2017 and expected to reach US$ 601.2 Mn by 2026, expanding at a CAGR of 5.7% from 2018 to 2026.

Market Insights
Vasculitis is a heterogeneous disease that has common clinical manifestation such as fibrinoid necrosis and inflammation of the blood vessels. The manifestation differ depending on the size of blood vessel. It is potentially a life threatening disease, however, if diagnosed early with immediate medical intervention the survival rate for one year increases to almost 90%. Large vessel vasculitis majorly consists of giant cell arteritis and Takayasu arteritis that are highly prevalent in Norway and Germany. Medium vessel vasculitis comprises polyarteritis nodusa which affects in all age group and mostly half of diagnosed cases have been related to HBV infection. Kawasaki disease is mostly seen in children below 4 years of age majorly affecting the coronary artery. Small vessel vasculitis comprises antineutrophil cytoplasmic autoantibodies (ANCA) associated vasculitis, Churg-Strauss syndrome and microscopic polyangitis, they usually occur in the small blood vessels innervating organs such as kidneys and lungs.

Biologics are leading the drug class segment due to better clinical outcomes in patients suffering with ANCA associated vasculitis and promising biological drugs in the pipeline with enhanced drug safety and efficacy. Cyclophosphamide is still the drug of choice for the treatment of vasculitis used in combination with prednisolone globally, highly recommended in patients showing resistance to rituximab treatment.

Large vessel vasculitis dominated the disease type segment in 2017 on account of increasing number of immunocompromised patients suffering with large vessel vasculitis and rising prevalence of CD4 T cell mediated Takayasu vasculitis in the Caucasian population. Small vessel vasculitis is anticipated to showcase impressive growth in the near future due to rising prevalence of ANCA associated small vessel vasculitis in the Mongolian population and rise in the occurrence of leukocytoclastic vasculitis with palpable purpura due to post viral syndromes and drugs.

North America dominated the vasculitis treatment market owing to the rising prevalence of large vessel vasculitis such as giant cell arteritis and Takayasu arteritis, developed healthcare infrastructure and domicile to key players actively engaged in the drug discovery for vasculitis treatment. Asia Pacific is set to register excellent growth during the forecast period due to increasing number of geriatric population suffering with small vessel vasculitis, proactive government initiatives to expedite the research activities related to vasculitis treatment and increasing disposable income making it affordable for the ailing patient to receive optimum treatment.
The prominent players actively engaged in the vasculitis treatment market are F.Hoffman La-Roche Ltd., AstraZeneca, Baxter International, Bristol Myers Squibb Company, Celgene Corporation, ChemoCentryx, Daiichi Sankyo, Eli Lilly & Company, GlaxoSmithKline Plc, Merck & Co. and Novartis AG.

Key Market Movements:
  • Rising prevalence of blood vessel inflammatory diseases
  • Technological advancement in the diagnostic kits resulting in accurate diagnosis of vasculitis due to overlapping disease manifestation with other inflammatory diseases
  • Recent FDA approved biologics contributing towards the growth of Vasculitis treatment market
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Baxter International
  • Celgene Corporaion
  • ChemoCentryx
  • Daiichi Sankyo
  • Eli Lilly & Company
  • MORE
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Vasculitis Treatment Market Portraiture
2.2. Global Vasculitis Treatment Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Vasculitis Treatment Market, by Disease Condition, 2017 (US$ Mn)
2.4. Global Vasculitis Treatment Market Share, by Geography, 2017 (US$ Mn)

Chapter 3. Vasculitis Treatment: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Vasculitis Treatment Market, by Key Players, 2017

Chapter 4. Global Vasculitis Treatment Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Biologics
4.2.1. Rituximab
4.2.2. Infliximab
4.2.3. Adalimumab
4.3. Corticosteroids
4.3.1. Prednisone
4.3.2. Methylprednisolone
4.4. Immunosuppressant
4.5. Pipeline Analysis
4.5.1. Tabular Representation of Phase I and Phase II Drugs

Chapter 5. Global Vasculitis Treatment Market, by Disease Condition, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Large Vessel Vasculitis
5.3. Medium Vessel Vasculitis
5.4. Small Vessel Vasculitis

Chapter 6. Global Vasculitis Treatment Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.1.1. North America Vasculitis Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.1.2. North America Vasculitis Treatment Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.1.3. North America Vasculitis Treatment Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe Vasculitis Treatment Market Analysis, 2016 – 2026
6.2.1. Europe Vasculitis Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.2.2. Europe Vasculitis Treatment Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.2.3. Europe Vasculitis Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific Vasculitis Treatment Market Analysis, 2016 – 2026
6.3.1. Asia Pacific Vasculitis Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.3.2. Asia Pacific Vasculitis Treatment Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.3.3. Asia Pacific Vasculitis Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America Vasculitis Treatment Market Analysis, 2016 – 2026
6.4.1. Latin America Vasculitis Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.4.2. Latin America Vasculitis Treatment Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.4.3. Latin America Vasculitis Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa Vasculitis Treatment Market, 2016 – 2026
6.5.1. Middle East & Africa Vasculitis Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.5.2. Middle East &Africa Vasculitis Treatment Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.5.3. Middle East & Africa Vasculitis Treatment Market Analysis, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa

Chapter 7. Company Profiles
7.1. F.Hoffman La Roche Ltd.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. AstraZeneca
7.3. Baxter International
7.4. Bristol Myers Squibb Company
7.5. Celgene Corporaion
7.6. ChemoCentryx
7.7. Daiichi Sankyo
7.8. Eli Lilly & Company
7.9. GlaxoSmithKline Plc
7.10. Merck & Co.

List of Figures
FIG 1. Vasculitis Treatment Market: Research Methodology
FIG 2. Vasculitis Treatment : Market Segmentation
FIG 3. Global Vasculitis Treatment Market, by Drug Class, 2017 (US$ Mn)
FIG 4. Global Vasculitis Treatment Market, by Disease Condition, 2017 (US$ Mn)
FIG 5. Global Vasculitis Treatment Market, by Geography, 2017 (US$ Mn)
FIG 6. Attractive Investment Proposition, by Geography, 2017
FIG 7. Competitive Analysis: Global Vasculitis Treatment Market, by Key Players, 2017
FIG 8. Global Rituximab Market in Vasculitis Treatment , 2016-2026(US$ Mn)
FIG 9. Global Infliximab Market in Vasculitis Treatment , 2016-2026 (US$ Mn)
FIG 10. Global Adalimumab Market in Vasculitis Treatment , 2016-2026 (US$ Mn)
FIG 11. Global Prednisone Market in Vasculitis Treatment , 2016-2026 (US$ Mn)
FIG 12. Global Methylprednisolone Market in Vasculitis Treatment , 2016-2026 (US$ Mn)
FIG 13. Global Immunosuppressant Market in Vasculitis Treatment , 2016-2026 (US$ Mn)
FIG 14. Global Large Vessel Vasculitis Market in Vasculitis Treatment , 2016-2026 (US$ Mn)
FIG 15. Global Medium Vessel Vasculitis Market in Vasculitis Treatment , 2016-2026 (US$ Mn)
FIG 16. Global Small Vessel Vasculitis Market in Vasculitis Treatment , 2016-2026 (US$ Mn)
FIG 17. U.S. Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 18. Canada Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 19. U.K. Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 20. Germany Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 21. Rest of Europe Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 22. China Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 23. Japan Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 24. Rest of Asia Pacific Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 25. Brazil Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 26. Mexico Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 27. Rest of Latin America Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 28. GCC Vasculitis Treatment Market, 2016-2026 (US$ Mn)
FIG 29. Rest of Middle East and Africa Vasculitis Treatment Market, 2016-2026 (US$ Mn)

List of Tables
TABLE 1 Global Vasculitis Treatment Market Portraiture
TABLE 2 Global Vasculitis Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global Biologics Market in Vasculitis Treatment , 2016 – 2026 (US$ Mn)
TABLE 4 Global Corticosteroids Market in Vasculitis Treatment , 2016 – 2026 (US$ Mn)
TABLE 5 Pipeline Analysis: Phase I and Phase II Drugs
TABLE 6 Global Vasculitis Treatment Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 7 Global Vasculitis Treatment Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 8 North America Vasculitis Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 North America Vasculitis Treatment Market, by Disease Condition, 2016 – 2026 (US$ Mn
TABLE 10 North America Vasculitis Treatment Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 11 Europe Vasculitis Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Europe Vasculitis Treatment Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 13 Europe Vasculitis Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Asia Pacific Vasculitis Treatment Market, by Drug Condition, 2016 – 2026 (US$ Mn)
TABLE 15 Asia Pacific Vasculitis Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 16 Asia Pacific Vasculitis Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 Latin America Vasculitis Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 18 Latin America Vasculitis Treatment Market, by Disease Condition, 2016 – 2026 (US$ Mn
TABLE 19 Latin America Vasculitis Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 Middle East and Africa Vasculitis Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 21 Middle East and Africa Vasculitis Treatment Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 22 Middle East and Africa Vasculitis Treatment Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 23 F.Hoffman La-Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 AstraZeneca: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Baxter International: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Bristol Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 ChemoCentryx: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Daiichi Sankyo: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • F.Hoffman La Roche Ltd.
  • AstraZeneca
  • Baxter International
  • Bristol Myers Squibb Company
  • Celgene Corporaion
  • ChemoCentryx
  • Daiichi Sankyo
  • Eli Lilly & Company
  • GlaxoSmithKline Plc
  • Merck & Co.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll